Wealthcare Advisory Partners’s VolitionRx Ltd VNRX Stock Holding History

Wealthcare Advisory Partners’s Portfolio VNRX Stock Details VNRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5	Closed	–	–	1831
2021 Q1	$0	Buy	+5	New	+$429	﹤0.01%	2117

Other funds holding VNRX

LIM

Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wealthcare Advisory Partners's VNRX Position: Q2 2021 in Review

Wealthcare Advisory Partners sold out of VolitionRx Ltd (VNRX) in Q2 2021, closing a stake of 5 shares.

Wealthcare Advisory Partners first reported a position in VNRX in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 46 funds tracked by Wall St. Rank hold VNRX as of Q2 2021.

Wealthcare Advisory Partners reported no remaining VolitionRx Ltd position as of Q2 2021 after selling out during the quarter.
Wealthcare Advisory Partners sold 5 VolitionRx Ltd shares in Q2 2021.
Wealthcare Advisory Partners first reported a position in VolitionRx Ltd in Q1 2021 and held it in 1 quarter.
Wealthcare Advisory Partners's VolitionRx Ltd position peaked at $0 in Q1 2021.
46 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q2 2021.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2021, filed 16 Aug 2021.